Manufacturing / Pharmaceutical Preparations
ROCKET PHARMACEUTICALS, INC.
RCKT
$3.39
+$0.03 (+0.88%)
Price as of Aug 4, 2026 23:17 UTC
340 M
Market Cap (Small Cap)
9%
IV Rank
134.3%
Implied Volatility
Aug 05
Next Earnings
Technical Signals
as of Aug 3
Mixed
3 of 7
Trend
- Above 20-day average $3.35
- Above 50-day average $3.39
- Above 200-day average $3.44 · -1.0%
- Moving averages stacked Not aligned
Momentum
- Golden cross (50/200) Down · 42d ago
- Momentum cross (20/50) Down · 4d ago
Volume
- Elevated volume 1.8x avg
Price & Trend
Daily candles with EMA 20, SMA 50. Drag to zoom.
Options Activity & Greeks
Implied volatility, flow, and dealer positioning from the options market.
Put/Call Ratio
0.00
Bullish skew
Implied Volatility
134.3%
0% percentile
IV vs Realized
Options rich
20d HV 62.7%
Options Heat Map
Delta-risk grid for RCKT options across strikes and expirations. Hover any cell for full Greeks.
Loading option chain data...
Insider Trades
2 buys
42 sells
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| Jun 18, 2026 | SOUTHWELL DAVID P | Grant | 22,862 | $0 | |
| Jun 18, 2026 | SOUTHWELL DAVID P | Grant | 64,860 | $0 | |
| Jun 18, 2026 | BOESS CARSTEN | Grant | 22,862 | $0 | |
| Jun 18, 2026 | BOESS CARSTEN | Grant | 64,860 | $0 | |
| Jun 18, 2026 | Malik Fady Ibraham | Grant | 22,862 | $0 | |
| Jun 18, 2026 | Malik Fady Ibraham | Grant | 64,860 | $0 | |
| Jun 18, 2026 | Dolsten Mikael | Grant | 22,862 | $0 | |
| Jun 18, 2026 | Dolsten Mikael | Grant | 64,860 | $0 | |
| Jun 18, 2026 | Fong Peter | Grant | 22,862 | $0 | |
| Jun 18, 2026 | Fong Peter | Grant | 64,860 | $0 |
Earnings History
| Date | Quarter | EPS Est. | EPS Actual | Surprise | Result |
|---|---|---|---|---|---|
| Mar 31, 2026 | Q1 2026 | -$0.42 | -$0.42 | -1.2% | Miss |
| Dec 31, 2025 | Q4 2025 | -$0.46 | -$0.38 | +17.8% | Beat |
| Sep 30, 2025 | Q3 2025 | -$0.52 | -$0.45 | +12.6% | Beat |
| Jun 30, 2025 | Q2 2025 | -$0.57 | -$0.59 | -3.9% | Miss |
Track RCKT with ThetaPal
Get insider trade alerts, AI portfolio analysis, and options roll recommendations for RCKT and your entire portfolio.